Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase EARLY_PHASE1 2Phase 4 1Phase 3 1

Status

Recruiting 31Completed 19Active not recruiting 18Terminated 11Not yet recruiting 6Withdrawn 3Unknown 2Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Glioblastoma 1Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × abemaciclib × Clear all
NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
CNS

Glioblastoma

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Academic and Community Cancer Research United

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT04272645 2020-07-15

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡